Herbert Y Meltzer

List of Publications by Year
in descending order

213 papers	19,293 citations	16451 64 h-index	11939 134 g-index
220 all docs	220 docs citations	220 times ranked	12771 citing authors

#	Article	IF	Citations
1	Schizophrenia risk loci from xMHC region were associated with antipsychotic response in chronic schizophrenic patients with persistent positive symptom. Translational Psychiatry, 2022, 12, 92.	4.8	5
2	Role of advanced glycation end products in the longitudinal association between muscular strength and psychotic symptoms among adolescents. NPJ Schizophrenia, 2022, 8, .	3.6	1
3	Repeated administration of rapastinel produces exceptionally prolonged rescue of memory deficits in phencyclidine-treated mice. Behavioural Brain Research, 2022, 432, 113964.	2.2	1
4	Schizophreniaâ€associated gene dysbindinâ€1 and tardive dyskinesia. Drug Development Research, 2021, 82, 678-684.	2.9	5
5	Development and Validation of a Computerized Adaptive Assessment Tool for Discrimination and Measurement of Psychotic Symptoms. Schizophrenia Bulletin, 2021, 47, 644-652.	4.3	11
6	Contrasting Typical and Atypical Antipsychotic Drugs. Focus (American Psychiatric Publishing), 2021, 19, 3-13.	0.8	16
7	An autophagy-related protein Becn2 regulates cocaine reward behaviors in the dopaminergic system. Science Advances, 2021, 7, .	10.3	9
8	Depolarizing GABA _A current in the prefrontal cortex is linked with cognitive impairment in a mouse model relevant for schizophrenia. Science Advances, 2021, 7, .	10.3	18
9	Awareness of illness moderates self-assessment of psychotic symptoms. Australian and New Zealand Journal of Psychiatry, 2021, , 000486742110574.	2.3	1
10	A functional HTR1A polymorphism, rs6295, predicts short-term response to lurasidone: confirmation with meta-analysis of other antipsychotic drugs. Pharmacogenomics Journal, 2020, 20, 260-270.	2.0	11
11	The effect of high vs. low dose lurasidone on eye movement biomarkers of prefrontal abilities in treatment-resistant schizophrenia. Schizophrenia Research, 2020, 215, 314-321.	2.0	5
12	Liver enzyme CYP2D6 gene and tardive dyskinesia. Pharmacogenomics, 2020, 21, 1065-1072.	1.3	4
13	M172. POLYGENIC RISK SCORES ANALYSES IN ANTIPSYCHOTIC-INDUCED WEIGHT GAIN. Schizophrenia Bulletin, 2020, 46, S202-S202.	4.3	0
14	Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol. Frontiers in Pharmacology, 2020, 11, 591.	3.5	8
15	Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action. Pharmacology Biochemistry and Behavior, 2020, 190, 172872.	2.9	14
16	Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia. Journal of Clinical Psychopharmacology, 2020, 40, 240-249.	1.4	30
17	Unmet Needs in Patients with Schizophrenia. , 2020, , 15-25.		0
18	Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans. Schizophrenia Research, 2019, 212, 204-212.	2.0	15

#	Article	IF	Citations
19	The Role of Dopamine D₃ Receptor Partial Agonism in Cariprazine-Induced Neurotransmitter Efflux in Rat Hippocampus and Nucleus Accumbens. Journal of Pharmacology and Experimental Therapeutics, 2019, 371, 517-525.	2.5	23
20	New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 94, 109659.	4.8	9
21	Association of Serotonin2c Receptor Polymorphisms With Antipsychotic Drug Response in Schizophrenia. Frontiers in Psychiatry, 2019, 10, 58.	2.6	13
22	Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma. Journal of Neuroscience, 2019, 39, 1982-1993.	3.6	65
23	The allosteric dopamine D1 receptor potentiator, DETQ, ameliorates subchronic phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice. Behavioural Brain Research, 2019, 361, 139-150.	2.2	21
24	Genetic validation study of protein tyrosine phosphatase receptor type D (PTPRD) gene variants and risk for antipsychotic-induced weight gain. Journal of Neural Transmission, 2019, 126, 27-33.	2.8	13
25	Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia. World Journal of Biological Psychiatry, 2019, 20, 91-95.	2.6	8
26	Hippocampal GABA A antagonism reverses the novel object recognition deficit in sub-chronic phencyclidine-treated rats. Behavioural Brain Research, 2018, 342, 11-18.	2.2	5
27	Dissecting the Functional Consequences of De Novo DNA Methylation Dynamics in Human Motor Neuron Differentiation and Physiology. Cell Stem Cell, 2018, 22, 559-574.e9.	11.1	53
28	Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes. Schizophrenia Research, 2018, 192, 194-204.	2.0	64
29	Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain. World Journal of Biological Psychiatry, 2018, 19, S97-S105.	2.6	11
30	F1. GENOME-WIDE ASSOCIATION STUDIES SUGGESTED ASSOCIATION BETWEEN DGKB AND ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN EUROPEANS AND AFRICAN AMERICANS. Schizophrenia Bulletin, 2018, 44, S218-S218.	4.3	0
31	Investigation of the HSPG2 Gene in Tardive Dyskinesia â€“ New Data and Meta-Analysis. Frontiers in Pharmacology, 2018, 9, 974.	3.5	17
32	T7. PHARMACOGENETIC OF TARDIVE DYSKINESIA -- A FOLLOW-UP ON THE VALBENAZINE TARGET VMAT2/SLC18A2. Schizophrenia Bulletin, 2018, 44, S115-S115.	4.3	0
33	5-HT1A parital agonism and 5-HT7 antagonism restore episodic memory in subchronic phencyclidine-treated mice: role of brain glutamate, dopamine, acetylcholine and GABA. Psychopharmacology, 2018, 235, 2795-2808.	3.1	22
34	Identifying the genetic risk factors for treatment response to lurasidone by genome-wide association study: A meta-analysis of samples from three independent clinical trials. Schizophrenia Research, 2018, 199, 203-213.	2.0	16
35	Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia. Neuroscience Letters, 2018, 686, 17-22.	2.1	7
36	TPA-023 attenuates subchronic phencyclidine-induced declarative and reversal learning deficits via GABAA receptor agonist mechanism: possible therapeutic target for cognitive deficit in schizophrenia. Neuropsychopharmacology, 2018, 43, 2468-2477.	5.4	11

#	Article	IF	Citations
37	A withinâ€subject consideration of the psychotic spectrum disorder concept in a patient in remission associated with cortical gray matter recovery. CNS Neuroscience and Therapeutics, 2018, 24, 641-651.	3.9	6
38	Association study between the neurexinâ€1 gene and tardive dyskinesia. Human Psychopharmacology, 2017, 32, e2568.	1.5	9
39	Dopamine D₄ receptor stimulation contributes to novel object recognition: Relevance to cognitive impairment in schizophrenia. Journal of Psychopharmacology, 2017, 31, 442-452.	4.0	26
40	Neurochemical arguments for the use of dopamine D 4 receptor stimulation to improve cognitive impairment associated with schizophrenia. Pharmacology Biochemistry and Behavior, 2017, 157, 16-23.	2.9	20
41	Replication of rs300774, a genetic biomarker near ACP1, associated with suicide attempts in patients with schizophrenia: Relation to brain cholesterol biosynthesis. Journal of Psychiatric Research, 2017, 94, 54-61.	3.1	19
42	RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia. Behavioural Brain Research, 2017, 332, 180-199.	2.2	19
43	5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice. Neuropsychopharmacology, 2017, 42, 2163-2177.	5.4	42
44	Muscarinic receptor signaling contributes to atypical antipsychotic drug reversal of the phencyclidine-induced deficit in novel object recognition in rats. Journal of Psychopharmacology, 2017, 31, 1588-1604.	4.0	13
45	Î”9-tetrahydrocannabinol (Î”9-THC) administration after neonatal exposure to phencyclidine potentiates schizophrenia-related behavioral phenotypes in mice. Pharmacology Biochemistry and Behavior, 2017, 159, 6-11.	2.9	21
46	Reduced Glutamatergic Currents and Dendritic Branching of Layer 5 Pyramidal Cells Contribute to Medial Prefrontal Cortex Deactivation in a Rat Model of Neuropathic Pain. Frontiers in Cellular Neuroscience, 2016, 10, 133.	3.7	76
47	Phencyclidine (PCP)â€“Induced Deficits in Novel Object Recognition. , 2016, , 723-732.		1
48	Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine. Molecular Neuropsychiatry, 2016, 2, 185-197.	2.9	14
49	Genetic association analysis of Nâ€methylâ€<scp>d</scp>â€aspartate receptor subunit gene GRIN2B and clinical response to clozapine. Human Psychopharmacology, 2016, 31, 121-134.	1.5	19
50	Gamma-Aminobutyric Acidergic Projections From the Dorsal Raphe to the Nucleus Accumbens Are Regulated by Neuromedin U. Biological Psychiatry, 2016, 80, 878-887.	1.3	25
51	Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response. Pharmacogenomics, 2016, 17, 103-109.	1.3	37
52	Serotonin (5-HT)1A receptor agonism and 5-HT7 receptor antagonism ameliorate the subchronic phencyclidine-induced deficit in executive functioning in mice. Psychopharmacology, 2016, 233, 649-660.	3.1	24
53	GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice. Behavioural Brain Research, 2016, 299, 105-110.	2.2	43
54	Association of orexin receptor polymorphisms with antipsychotic-induced weight gain. World Journal of Biological Psychiatry, 2016, 17, 221-229.	2.6	24

#	Article	IF	Citations
55	Nicotinic receptors and lurasidone-mediated reversal of phencyclidine-induced deficit in novel object recognition. Behavioural Brain Research, 2016, 301, 204-212.	2.2	24
56	Prolonged reversal of the phencyclidine-induced impairment in novel object recognition by a serotonin (5-HT)1A-dependent mechanism. Behavioural Brain Research, 2016, 301, 132-141.	2.2	11
57	Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus. Neuropharmacology, 2016, 100, 90-97.	4.1	36
58	The brainâ€derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia. Bipolar Disorders, 2015, 17, 528-535.	1.9	52
59	A Mouse Model of Human Primitive Neuroectodermal Tumors Resulting from Microenvironmentally-Driven Malignant Transformation of Orthotopically Transplanted Radial Glial Cells. PLoS ONE, 2015, 10, e0121707.	2.5	6
60	Attention Must Be Paid: The Association of Plasma Clozapine/NDMC Ratio With Working Memory. American Journal of Psychiatry, 2015, 172, 502-504.	7.2	18
61	Involvement of Cholinergic System in Hyperactivity in Dopamine-Deficient Mice. Neuropsychopharmacology, 2015, 40, 1141-1150.	5.4	27
62	Pharmacotherapy of cognition in schizophrenia. Current Opinion in Behavioral Sciences, 2015, 4, 115-121.	3.9	26
63	Enantioselective Syntheses of Heteroyohimbine Natural Products: A Unified Approach through Cooperative Catalysis. Angewandte Chemie - International Edition, 2015, 54, 6900-6904.	13.8	25
64	Combined serotonin (5-HT)1A agonism, 5-HT2A and dopamine D2 receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats. Behavioural Brain Research, 2015, 285, 165-175.	2.2	24
65	Decreased serotonin2C receptor responses in male patients with schizophrenia. Psychiatry Research, 2015, 226, 308-315.	3.3	4
66	Identification of the role of bone morphogenetic protein (<scp>BMP</scp>) and transforming growth factorâ€Î² (TGFâ€Î²) signaling in the trajectory of serotonergic differentiation in a rapid assay in mouse embryonic stem cells in vitro. Journal of Neurochemistry, 2015, 132, 418-428.	3.9	11
67	Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement. Pharmacology Biochemistry and Behavior, 2015, 138, 49-57.	2.9	25
68	A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia. Journal of Clinical Psychiatry, 2015, 76, 1085-1090.	2.2	99
69	A Hypothesis-Driven Association Study of 28 Nuclear-Encoded Mitochondrial Genes with Antipsychotic-Induced Weight Gain in Schizophrenia. Neuropsychopharmacology, 2014, 39, 1347-1354.	5.4	26
70	The alpha-7 nicotinic receptor partial agonist/5-HT3 antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release. Psychopharmacology, 2014, 231, 2199-2210.	3.1	24
71	The novel Î±7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. Psychopharmacology, 2014, 231, 4541-4551.	3.1	45
72	A genetic locus in 7p12.2 associated with treatment resistant schizophrenia. Schizophrenia Research, 2014, 159, 333-339.	2.0	22

#	Article	IF	Citations
73	Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5â€<scp>HT</scp>)_{2A} and <scp>DA</scp> D₂ antagonism and 5â€<scp>HT</scp>_{1A} partial agonism. Journal of Neurochemistry, 2014, 128, 938-949.	3.9	66
74	Clozapine Acts as an Agonist at Serotonin 2A Receptors to Counter MK-801-Induced Behaviors through a Î²Arrestin2-Independent Activation of Akt. Neuropsychopharmacology, 2014, 39, 1902-1913.	5.4	47
75	Schizophrenia and Suicide: Treatment Optimization. Current Treatment Options in Psychiatry, 2014, 1, 149-162.	1.9	2
76	Language-dependent performance on the letter fluency task in patients with schizophrenia. Schizophrenia Research, 2014, 152, 421-429.	2.0	9
77	No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain. Psychiatry Research, 2014, 219, 255-260.	3.3	13
78	The Novel Object Recognition Test in Rodents in Relation to Cognitive Impairment in Schizophrenia. Current Pharmaceutical Design, 2014, 20, 5104-5114.	1.9	132
79	Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. Journal of Psychiatric Research, 2013, 47, 1760-1765.	3.1	55
80	D1 receptor agonists reverse the subchronic phencyclidine (PCP)-induced novel object recognition (NOR) deficit in female rats. Behavioural Brain Research, 2013, 238, 36-43.	2.2	38
81	Update on Typical and Atypical Antipsychotic Drugs. Annual Review of Medicine, 2013, 64, 393-406.	12.2	337
82	Translating the N-methyl-d-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia. International Journal of Neuropsychopharmacology, 2013, 16, 2181-2194.	2.1	103
83	Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtypeâ€“targeted drugs. Journal of Clinical Investigation, 2013, 123, 4986-4991.	8.2	100
84	Prevention of the Phencyclidine-Induced Impairment in Novel Object Recognition in Female Rats by Co-Administration of Lurasidone or Tandospirone, a 5-HT1A Partial Agonist. Neuropsychopharmacology, 2012, 37, 2175-2183.	5.4	41
85	The Novel Antipsychotic Drug Lurasidone Enhances N-Methyl-d-aspartate Receptor-Mediated Synaptic Responses. Molecular Pharmacology, 2012, 81, 113-119.	2.3	34
86	5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux. NeuroReport, 2012, 23, 436-440.	1.2	40
87	Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day. Schizophrenia Research, 2012, 141, 144-152.	2.0	87
88	Investigating association of four gene regions (GABRB3, MAOB, PAH, and SLC6A4) with five symptoms in schizophrenia. Psychiatry Research, 2012, 198, 202-206.	3.3	20
89	Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: Replication and exploration. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 37, 62-75.	4.8	34
90	Serotonergic Mechanisms as Targets for Existing and Novel Antipsychotics. Handbook of Experimental Pharmacology, 2012, , 87-124.	1.8	88

#	Article	IF	Citations
91	Clozapine. Clinical Schizophrenia and Related Psychoses, 2012, 6, 134-144.	1.4	183
92	Association of FAS, a TNF-Î± receptor gene, with treatment resistant schizophrenia. Schizophrenia Research, 2011, 129, 211-212.	2.0	9
93	The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response. Schizophrenia Research, 2011, 132, 121-124.	2.0	24
94	5-HT2A and 5-HT2C receptor stimulation are differentially involved in the cortical dopamine effluxâ€"Studied in 5-HT2A and 5-HT2C genetic mutant mice. European Journal of Pharmacology, 2011, 652, 40-45.	3.5	21
95	The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology, 2011, 213, 289-305.	3.1	108
96	Interaction of mGlu2/3 agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. Psychopharmacology, 2011, 217, 13-24.	3.1	56
97	Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study. American Journal of Psychiatry, 2011, 168, 957-967.	7.2	228
98	A 12-Month Randomized, Open-Label Study of the Metabolic Effects of Olanzapine and Risperidone in Psychotic Patients. Journal of Clinical Psychiatry, 2011, 72, 1602-1610.	2.2	40
99	Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response. Human Psychopharmacology, 2010, 25, 582-585.	1.5	16
100	Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis. Neuropsychopharmacology, 2010, 35, 881-892.	5.4	265
101	Common variants conferring risk of schizophrenia: A pathway analysis of GWAS data. Schizophrenia Research, 2010, 122, 38-42.	2.0	190
102	A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. Psychiatry Research, 2010, 177, 286-293.	3.3	24
103	Differential Effects of M1 and 5-Hydroxytryptamine1A Receptors on Atypical Antipsychotic Drug-Induced Dopamine Efflux in the Medial Prefrontal Cortex. Journal of Pharmacology and Experimental Therapeutics, 2009, 330, 948-955.	2.5	21
104	A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia. PLoS Genetics, 2009, 5, e1000373.	3.5	383
105	Comparative Effectiveness Research For Antipsychotic Medications: How Much Is Enough?. Health Affairs, 2009, 28, w794-w808.	5.2	16
106	Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology, 2009, 205, 119-128.	3.1	240
107	Determinants of work outcome in schizophrenia and schizoaffective disorder: Role of cognitive function. Psychiatry Research, 2009, 169, 178-179.	3.3	41
108	Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine. European Journal of Pharmacology, 2008, 596, 89-97.	3.5	18

#	Article	IF	Citations
109	Association of Sult4A1 SNPs with psychopathology and cognition in patients with schizophrenia or schizoaffective disorder. Schizophrenia Research, 2008, 106, 258-264.	2.0	33
110	Does stimulation of 5-HT1A receptors improve cognition in schizophrenia?. Behavioural Brain Research, 2008, 195, 98-102.	2.2	153
111	Antipsychotic Drugs: Comparison in Animal Models of Efficacy, Neurotransmitter Regulation, and Neuroprotection. Pharmacological Reviews, 2008, 60, 358-403.	16.0	213
112	Asenapine Increases Dopamine, Norepinephrine, and Acetylcholine Efflux in the Rat Medial Prefrontal Cortex and Hippocampus. Neuropsychopharmacology, 2008, 33, 2934-2945.	5.4	46
113	Oakley Ray, 1931â€“2007. Neuropsychopharmacology, 2008, 33, 2783-2784.	5.4	0
114	In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Progress in Brain Research, 2008, 172, 177-197.	1.4	210
115	Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder. Journal of Clinical Psychopharmacology, 2008, 28, 392-400.	1.4	89
116	A Randomized, Double-Blind Comparison of Clozapine and High-Dose Olanzapine in Treatment-Resistant Patients With Schizophrenia. Journal of Clinical Psychiatry, 2008, 69, 274-285.	2.2	136
117	Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 3019-3020.	7.1	21
118	WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Preclinical Antipsychotic-Like Activity. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 486-496.	2.5	142
119	Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial. Archives of General Psychiatry, 2007, 64, 633.	12.3	928
120	A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: Dose effects and comparison to practice effects. Schizophrenia Research, 2007, 89, 211-224.	2.0	125
121	5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus. Brain Research, 2007, 1134, 70-78.	2.2	57
122	Aripiprazole for Treatment-Resistant Schizophrenia. Journal of Clinical Psychiatry, 2007, 68, 213-223.	2.2	100
123	Interpreting the Efficacy Findings in the CATIE Study: What Clinicians Should Know. CNS Spectrums, 2006, 11, 14-24.	1.2	39
124	Effects of divalproex and atypical antipsychotic drugs on dopamine and acetylcholine efflux in rat hippocampus and prefrontal cortex. Brain Research, 2006, 1099, 44-55.	2.2	33
125	Testing Multiple Novel Mechanisms for Treating Schizophrenia in a Single Trial. Progress in Neurotherapeutics and Neuropsychopharmacology, 2006, 1, 115-120.	0.0	0
126	Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment. American Journal of Psychiatry, 2006, 163, 600-610.	7.2	760

#	Article	IF	Citations
127	The metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?. International Journal of Neuropsychopharmacology, 2005, 8, 153-156.	2.1	28
128	ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology, 2005, 183, 144-153.	3.1	55
129	Association study of 12 polymorphisms spanning the dopamine D2 receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology, 2005, 181, 179-187.	3.1	90
130	A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. International Journal of Neuropsychopharmacology, 2005, 8, 457-472.	2.1	516
131	A Double-Blind Controlled Study of Adjunctive Treatment With Risperidone in Schizophrenic Patients Partially Responsive to Clozapine. Journal of Clinical Psychiatry, 2005, 66, 63-72.	2.2	166
132	Suicide in Schizophrenia, Clozapine, and Adoption of Evidence-Based Medicine. Journal of Clinical Psychiatry, 2005, 66, 530-533.	2.2	48
133	Serotonin 1A Receptors in Memory Function. American Journal of Psychiatry, 2004, 161, 1505-1505.	7.2	26
134	Cognitive Factors in Schizophrenia: Causes, Impact, and Treatment. CNS Spectrums, 2004, 9, 15-24.	1.2	52
135	Placebo-Controlled Evaluation of Four Novel Compounds for the Treatment of Schizophrenia and Schizoaffective Disorder. American Journal of Psychiatry, 2004, 161, 975-984.	7.2	330
136	Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. European Journal of Pharmacology, 2004, 493, 75-83.	3.5	175
137	Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism. Brain Research, 2004, 1023, 54-63.	2.2	81
138	Atypical antipsychotic drugs improve cognition in schizophrenia. Biological Psychiatry, 2003, 53, 265-267.	1.3	34
139	Clozapine-induced weight gain predicts improvement in psychopathology. Schizophrenia Research, 2003, 59, 19-27.	2.0	123
140	Serotonin receptors : their key role in drugs to treat schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 1159-1172.	4.8	670
141	H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs. Neuropsychopharmacology, 2003, 28, 519-526.	5.4	694
142	Clozapine Treatment for Suicidality in Schizophrenia<subtitle>International Suicide Prevention Trial (InterSePT)</subtitle>. Archives of General Psychiatry, 2003, 60, 82.	12.3	1,200
143	Reply: H1-histamine Receptor Affinity Predicts Short-term Weight Gain for Typical and Atypical Antipsychotic Drugs. Neuropsychopharmacology, 2003, 28, 2210-2211.	5.4	5
144	Beyond Control of Acute Exacerbation: Enhancing Affective and Cognitive Outcomes. CNS Spectrums, 2003, 8, 16-18.	1.2	8

#	Article	IF	Citations
145	5-HT1A and 5-HT2A receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. Brain Research, 2002, 939, 34-42.	2.2	48
146	5-HT2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Research, 2002, 947, 157-165.	2.2	123
147	Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Research, 2002, 956, 349-357.	2.2	204
148	Atypical, but Not Typical, Antipsychotic Drugs Increase Cortical Acetylcholine Release without an Effect in the Nucleus Accumbens or Striatum. Neuropsychopharmacology, 2002, 26, 325-339.	5.4	218
149	Responseâ‹†. Neuropsychopharmacology, 2002, 26, 409.	5.4	0
150	SR46349-B, a 5-HT2A/2C Receptor Antagonist, Potentiates Haloperidol-induced Dopamine Release in Rat Medial Prefrontal Cortex and Nucleus Accumbens. Neuropsychopharmacology, 2002, 27, 430-441.	5.4	71
151	Commentary on "Clinical studies on the mechanism of action of clozapine; the dopamineâ€“serotonin hypothesis of schizophrenia." Psychopharmacology (1989) 99:S18â€“S27. Psychopharmacology, 2002, 163, 1-3.	3.1	37
152	Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. Journal of Clinical Psychiatry, 2002, 63 Suppl 9, 25-9.	2.2	11
153	The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia. Biological Psychiatry, 2001, 49, 861-868.	1.3	150
154	Perospirone. CNS Drugs, 2001, 15, 338.	5.9	0
155	5â€HT‹sub›2A‹/sub› and D‹sub›2‹/sub› receptor blockade increases cortical DA release via 5â€HT‹sub›1A‹/sub› receptor activation: a possible mechanism of atypical antipsychoticâ€induced cortical dopamine release. Journal of Neurochemistry, 2001, 76, 1521-1531.	3.9	490
156	Enhancement of Cognitive Performance in Schizophrenia by Addition of Tandospirone to Neuroleptic Treatment. American Journal of Psychiatry, 2001, 158, 1722-1725.	7.2	195
157	Treatment of Suicidality in Schizophrenia. Annals of the New York Academy of Sciences, 2001, 932, 44-60.	3.8	96
158	Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message?. Psychopharmacology, 2000, 150, 349-350.	3.1	65
159	Effect of Adjunctive Treatment With Serotonin-1A Agonist Tandospirone on Memory Functions in Schizophrenia. Journal of Clinical Psychopharmacology, 2000, 20, 386-388.	1.4	61
160	Clozapine pretreatment modifies haloperidol-elicited forebrain Fos induction: a regionally-specific double dissociation. Psychopharmacology, 1999, 144, 255-263.	3.1	28
161	Association of the MscI Polymorphism of the Dopamine D3 Receptor Gene with Tardive Dyskinesia in Schizophrenia. Neuropsychopharmacology, 1999, 21, 17-27.	5.4	147
162	Brain Noradrenergic Receptors in Major Depression and Schizophrenia. Neuropsychopharmacology, 1999, 21, 69-81.	5.4	64

#	Article	IF	Citations
163	The Role of Serotonin in Antipsychotic Drug Action. Neuropsychopharmacology, 1999, 21, 106S-115S.	5.4	615
164	Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. European Archives of Psychiatry and Clinical Neuroscience, 1999, 249, S90-S98.	3.2	100
165	Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. European Journal of Pharmacology, 1998, 351, 163-171.	3.5	80
166	Effects of Desmethylclozapine on Fos Protein Expression in the Forebrain: In Vivo Biological Activity of the Clozapine Metabolite. Neuropsychopharmacology, 1998, 19, 99-103.	5.4	24
167	Serotonin Subtype 2 Receptor Genes and Clinical Response to Clozapine in Schizophrenia Patients. Neuropsychopharmacology, 1998, 19, 123-132.	5.4	220
168	The Evolution of Treatment Resistance: Biologic Implications. Journal of Clinical Psychopharmacology, 1998, 18, 5S-11S.	1.4	28
169	INTRODUCTION. Journal of Clinical Psychopharmacology, 1998, 18, 1S.	1.4	5
170	Treatment-Resistant Schizophrenia - The Role of Clozapine. Current Medical Research and Opinion, 1997, 14, 1-20.	1.9	403
171	Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Research, 1997, 66, 1-11.	3.3	322
172	Serotonin Receptors in Suicide Victims with Major Depression. Neuropsychopharmacology, 1997, 16, 162-173.	5.4	130
173	The Effect of Streptozotocin-Induced Diabetes on Dopamine2, Serotonin1A and Serotonin2A Receptors in the Rat Brain. Neuropsychopharmacology, 1997, 16, 183-190.	5.4	37
174	Fluoxetine, but not Tricyclic Antidepressants, Potentiates the 5-Hydroxytryptophan-Mediated Increase in Plasma Cortisol and Prolactin Secretion in Subjects with Major Depression or with Obsessive Compulsive Disorder. Neuropsychopharmacology, 1997, 17, 1-11.	5.4	62
175	Effects of meta-chlorophenylpiperazine on neuroendocrine and behavioral responses in male schizophrenic patients and normal volunteers. Psychiatry Research, 1996, 64, 147-159.	3.3	20
176	Pre-clinical Pharmacology of Atypical Antipsychotic Drugs: A Selective Review. British Journal of Psychiatry, 1996, 168, 23-31.	2.8	61
177	Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia. Brain Research, 1996, 708, 209-214.	2.2	155
178	Cloning, Characterization, and Chromosomal Localization of a Human 5â€HT₆ Serotonin Receptor. Journal of Neurochemistry, 1996, 66, 47-56.	3.9	329
179	Dr. Meltzer and Mr. Cola Reply. American Journal of Psychiatry, 1995, 152, 153-154.	7.2	125
180	Plasma Clozapine Levels and the Treatment of L-DOPA-Induced Psychosis in Parkinson's Disease. Neuropsychopharmacology, 1995, 12, 39-45.	5.4	44

#	Article	IF	Citations
181	Association study between the dopamine D4 receptor gene and schizophrenia. American Journal of Medical Genetics Part A, 1995, 60, 452-455.	2.4	49
182	Association study of dopamine D3 receptor gene and schizophrenia. American Journal of Medical Genetics Part A, 1995, 60, 558-562.	2.4	52
183	Plasma Clozapine and Desmethylclozapine Levels in Clozapine-Induced Agranulocytosis. Neuropsychopharmacology, 1994, 11, 45-47.	5.4	33
184	Effect of Clozapine Treatment on Serotonin-2â€"Receptor Binding in the Blood Platelets of Schizophrenic Patients. Neuropsychopharmacology, 1994, 10, 109-114.	5.4	13
185	The Effect of Apomorphine, MK-212 (6-chloro-2-[1-piperazinyl]-pyrazine) and Placebo on Smooth Pursuit Gain and Corrective Saccades in Normal Subjects. Neuropsychopharmacology, 1994, 11, 49-62.	5.4	14
186	Nâ€ɗesmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. British Journal of Haematology, 1994, 86, 555-561.	2.5	82
187	Blunted oral body temperature response to MK-212 in cocaine addicts. Drug and Alcohol Dependence, 1994, 35, 217-222.	3.2	20
188	Recent advances in the pharmacotherapy of schxzophrenia. Acta Psychiatrica Scandinavica, 1994, 90, 95-101.	4.5	59
189	RELATIONSHIP BETWEEN POSITIVE AND NEGATIVE SYMPTOMS: RESPONSE TO ANTIPSYCHOTIC DRUGS AND STRUCTURAL BRAIN ABNORMALITIES. , 1994, , .		0
190	Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry, 1993, 34, 702-712.	1.3	366
191	Mechanisms of Clozapineâ€Induced Agranulocytosis. Drug Safety, 1992, 7, 17-25.	3.2	83
192	Effect of the serotonin agonist, MK-212, on body temperature in schizophrenia. Biological Psychiatry, 1992, 31, 460-470.	1.3	18
193	The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo. Brain Research, 1992, 574, 98-104.	2.2	34
194	Amperozide, a Novel Antipsychotic Drug, Inhibits the Ability of d-Amphetamine to Increase Dopamine Release In Vivo in Rat Striatum and Nucleus Accumbens. Journal of Neurochemistry, 1992, 58, 2285-2291.	3.9	54
195	Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated cortisol, ACTH and prolactin secretion in humans. Psychopharmacology, 1991, 103, 258-264.	3.1	56
196	Effect of 3,4-Methylenedioxymethamphetamine on 3,4-Dihydroxyphenylalanine Accumulation in the Striatum and Nucleus Accumbens. Journal of Neurochemistry, 1990, 54, 1062-1067.	3.9	48
197	Serotonergic Dysfunction in Depression. British Journal of Psychiatry, 1989, 155, 25-31.	2.8	192
198	Selective cross-tolerance to 5-HT1A and 5-HT2 receptor-mediated temperature and corticosterone responses. Pharmacology Biochemistry and Behavior, 1989, 33, 781-785.	2.9	37

#	Article	IF	Citations
199	Basic biology of clozapine: electrophysiological and neuroendocrinological studies. Psychopharmacology, 1989, 99, S13-S17.	3.1	37
200	Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology, 1989, 99, S18-S27.	3.1	534
201	Clozapine: New research on efficacy and mechanism of action. European Archives of Psychiatry and Neurological Sciences, 1989, 238, 332-339.	0.9	92
202	Effect of typical and atypical antipsychotic drugs on 5-HT2 receptor density in rat cerebral cortex. Life Sciences, 1989, 45, 1397-1406.	4.3	82
203	Melperone and clozapine: neuroendocrine effects of atypical neuroleptic drugs. Acta Psychiatrica Scandinavica, 1989, 80, 24-29.	4.5	28
204	Duration of a Clozapine Trial in Neuroleptic-Resistant Schizophrenia. Archives of General Psychiatry, 1989, 46, 672.	12.3	65
205	Novel approaches to the pharmacotherapy of schizophrenia. Drug Development Research, 1986, 9, 23-40.	2.9	34
206	Suppression of the hypo- and hyperthermic responses to 5-HT agonists following the repeated administration of monoamine oxidase inhibitors. Psychopharmacology, 1986, 90, 403-7.	3.1	23
207	Differential Effect of Subchronic Treatment with Various Neuroleptic Agents on Serotonin2Receptors in Rat Cerebral Cortex. Journal of Neurochemistry, 1986, 46, 191-197.	3.9	84
208	Descriptive studies of H-reflex recovery curves in psychiatric patients. Psychological Medicine, 1980, 10, 541-548.	4.5	22
209	Behavioral rating scales for assessing phencyclidine-induced locomotor activity, stereotypes behavior and ataxia in rats. European Journal of Pharmacology, 1979, 59, 169-179.	3.5	225
210	Serum Creatine Phosphokinase Activity in Acute Psychosis. British Journal of Psychiatry, 1973, 122, 369-369.	2.8	0
211	Muscle Abnormalities in Acute Psychoses. Archives of General Psychiatry, 1970, 23, 481.	12.3	61
212	Testing multiple novel mechanisms for treating schizophrenia in a single trial. , 0, , 115-120.		2
213	The Neurobiology of Schizophrenia. , 0, , 301-316.		11